Data updated: Sep 20, 2026
CARBON DIOXIDE, USP (carbon dioxide) · LINDE MERCHANT PRODUCTIONS INC
X-Ray Contrast Activity
Respiratory
Approved 2013-07-05
18
Indications
--
Phase 3 Trials
13
Years on Market
Details
- Status
- Prescription
- First Approved
- 2013-07-05
- Routes
- INHALATION
- Dosage Forms
- GAS
Companies
LINDE MERCHANT PRODUCTIONS INC LINDE GAS EQUIP LINDE NORTH AMERICA INC LISS AMERICA LLC WELDERS SUPPLY COMPANY OF LOUISVILLE INC PRAXAIR INC CONTINENTAL CARBONIC PRODUCTS, INC. NEXAIR LLC DJB GAS SERVICES, INC RELIANT HOLDINGS LTD AIRGAS CARBONIC INC AIRGAS USA LLC MIDDLESEX GASES TECHNOLOGIES, INC. HAUN SPECIALTY GASES INC GENERAL DISTRIBUTING COMPANY ROBERTS OXYGEN CO INC A-OX WELDING SUPPLY CO, INC. CENTRAL WELDING SUPPLY MITCHELL WEDLING SUPPLY
Active Ingredient: CARBON DIOXIDE
Website: ↗
CARBON DIOXIDE, USP Approval History
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
19 FDA actions from 2013 to 2025
Aug 2017 ORIGINAL
Update
What CARBON DIOXIDE, USP Treats
18 FDA approvalsOriginally approved for its first indication in 2013 . Covers 18 distinct patient populations.
- Other (18)
Other
(18 approvals)- • Approved indication (Jul 2013)Letter
- • Approved indication (Jul 2013)Letter
- • Approved indication (Jul 2013)Letter
- • Approved indication (Sep 2013)Letter
- • Approved indication (May 2014)Letter
- • Approved indication (Aug 2017)
- • Approved indication (Jun 2019)Letter
- • Approved indication (Jul 2020)Letter
- • Approved indication (Oct 2021)Letter
- • Approved indication (Feb 2022)Letter
- • Approved indication (Apr 2022)Letter
- • Approved indication (Feb 2024)Letter
- • Approved indication (Aug 2024)Letter
- • Approved indication (Nov 2024)Letter
- • Approved indication (Feb 2025)Letter
- • Approved indication (Apr 2025)Letter
- • Approved indication (Jun 2025)Letter
- • Approved indication (Oct 2025) NewLetter
📋
Clinical Trial Registry
3 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT02473354 (OIRD) | Pro00060429 | Ph 1 | completed | Predictors of Opioid-Induced Respiratory Depression (OIRD) |
| NCT02113449 results posted | 202181 RH01910 | Ph 2 | completed | Market Potential of Carbon Dioxide Nasal Spray |
| NCT07420530 EILO | 29009 R01DC023381 | Ph 2 | recruiting | Respiratory and Real-time Dynamics in Exercise-Induced Paradoxical Vocal Fold Motion |
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CARBON DIOXIDE, USP FDA Label Details
Track CARBON DIOXIDE, USP with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.